Montreal, Quebec 08 August 2011 — Enobia Pharma Inc., a clinical stage biotech company focused on developing novel therapeutics for serious bone disorders, today announced that it has raised US$40 million through the private placement of approximately 13,724,000 shares of its common stock to new pharmaceutical and financial investors. The proceeds will be used to fund the ongoing development of ENB-0040, Enobia’s enzyme replacement therapy (ERT) for hypophosphatasia, a rare and potentially life threatening genetic bone disorder for which there is no currently approved therapy. BofA Merrill Lynch acted as the exclusive placement agent to the company.

“We are pleased by the strong interest from both strategic and financial investors. We look forward to building a first rate biopharmaceutical company focused on rare genetic bone diseases,” said Enobia Chairman and OrbiMed General Partner Jonathan Silverstein.

Enobia has completed two 6-month clinical studies in hypophosphatasia; a phase I/II study initiated in October 2008 in infants and young children with life threatening hypophosphatasia, and a phase II study in children aged 5-12. These patients continue to receive therapy in ongoing extension studies. Updates of infantile and juvenile data will be given at the upcoming SSIEM (September 2, 2011 Geneva Switzerland) and ASBMR (September 16, 2011 San Diego, CA) meetings. Enobia is also enrolling additional infants and children with severe hypophosphatasia under the age of 5.

One year treatment results from a Phase II study in adolescents and adults with hypophosphatasia will be available in the first half of 2012. ENB-0040 manufactured at commercial scale is now being used in clinical trials.

Enobia was also recently awarded a US$1.2 million FDA Orphan Grant for the long-term ENB-0040 treatment of infants and young children with life-threatening or severely debilitating hypophosphatasia. Enobia will receive these funds over the next three years with the opportunity to apply for additional funding in subsequent years.

About ENB-0040
There are currently no therapies approved for hypophosphatasia (HPP), a rare inherited metabolic disease characterized primarily by defective bone mineralization with multi-systemic sequelae caused by a deficiency in the enzyme tissue non-specific alkaline phosphatase (TNSALP). ENB-0040 (asfotase alfa) is an investigational subcutaneous enzyme replacement therapy for HPP. ENB-0040 is designed to directly target TNSALP to the bone in order to correct the enzyme deficiency, which could lead to restoration of normal bone mineralization and function. ENB-0040, awarded orphan designation in the U.S. and EU in 2008 and Fast Track status in 2009, is currently in Phase IIb clinical development.

About Enobia Pharma Inc.
Enobia Pharma Inc. is a private Montreal based company focused on the development of therapeutics to treat serious bone disorders for which there are no drug therapies currently approved. ENB-0040, an investigational drug for the treatment of hypophosphatasia, is the Company’s lead program. For more information, please visit www.enobia.com.

Company Contact:
Julie Anne Smith, Enobia Pharma Inc.
(514) 596-2901, extension 214

Media Contact (United States):
Liz Falcone, Feinstein Kean Healthcare
617-761-6727

Media Contact (Canada):
Jean-Pierre Trudel, APR, Jean-Pierre Trudel and Associates
(514) 347-6111

09 June 2011 – New Section 2(ee) for REQUIEM 25EC in Leafy Vegetables

Winnipeg, Manitoba  14 April 2011 – Manitoba Harvest Hemp Foods & Oils is pleased to announce that it has been named a finalist in the inaugural HSBC International Business Awards, which celebrate the best of Canadian companies doing business abroad.

Developed by HSBC Bank Canada in partnership with Business without Borders, the awards honor Canadian firms that have made a real difference in taking their products and services to the world. Manitoba Harvest is recognized as one of three finalists in the Small and Medium Enterprise category, highlighting its strong growth trajectory in the U.S. market and its commitment to corporate social responsibility initiatives.

“It’s an honor to receive recognition as one of HSBC’s International Business Award finalists. It’s a testament to the vision and dedication of the Manitoba Harvest team, who continues to drive our company’s growth in a strategic and responsible way, from ingredient sourcing initiatives to environmental and social stewardship,” said Mike Fata, CEO and co-founder of Manitoba Harvest.

Manitoba Harvest’s top export is shelled hemp seed, also known as “hemp hearts.” The company also exports hemp protein powder, Hemp Bliss organic hemp beverage, hemp seed butter and hemp oil. The company strives to conduct business in a responsible way, sourcing hemp seed from local farmers to create a closed-loop system that fosters collaboration and fairness. The company also utilizes energy efficient facilities, sources renewable energy credits to offset electrical usage, and all products are offered in re-usable or recyclable packaging.

“We are thoroughly impressed with the caliber of performance and results seen in our twelve finalists,” said Mark Watkinson, Senior Executive Vice President, Head of Commercial Banking, North America, HSBC. “We were particularly impressed by the diversity of industries and Canadian regions represented, as these speak volumes to Canadian companies successfully translating opportunity into success. While only four winners will emerge, all finalists deserve our attention and respect.”

Finalists and winners will be honored at a gala celebration on the evening of May 10, 2011, at the Art Gallery of Ontario, in Toronto. Brett Wilson, entrepreneur, philanthropist and CBC Dragon’s Den panel member will be the master of ceremonies.

About Manitoba Harvest Hemp Foods & Oils
Founded in 1998, Manitoba Harvest Hemp Foods & Oils is the world’s largest vertically-integrated, farmer owned hemp food manufacturer. Manitoba Harvest is proud to offer award-winning products like Hemp Pro 70® (hemp protein concentrate), Hemp Bliss® Organic Hemp Beverage, shelled hemp seed, and hemp oil. In addition to their own popular brand of hemp foods, Manitoba Harvest supplies many other leading consumer brands with functional hemp food ingredients. www.manitobaharvest.com.

About HSBC Bank Canada
HSBC Bank Canada, a subsidiary of HSBC Holdings plc, has more than 260 offices, including over 140 bank branches, and is the leading international bank in Canada. With around 7,500 offices in 87 countries and territories and assets of US$2,455 billion at 31 December 2010, the HSBC Group is one of the world’s largest banking and financial services organizations.

About Business without Borders
Canada’s newest and best source of news and information for companies seeking to do business beyond this nation’s borders, Business without Borders was created by HSBC Bank Canada in association with Rogers Publishing Limited and the Globe and Mail. Business without Borders provides news, analysis, tools and inspiring profiles of Canadian businesses that are exporting, expanding their operations and sales abroad or relocating operations to other countries.

15 March 2011 – Chromatin Announces Dual-Purpose Hybrid Sorghum For Sugar And Bioenergy Production

08 March 2011 – Advanta US and Chromatin, Inc. Announce Commercial License Agreement for Sorghum Germplas

Quebec City, Quebec 21 February 2011 – Biopharmacopae Design International Inc. (“Biopharmacopae”), a company specialized in the discovery and development of innovative, science-based, plant-derived ingredients and products for the nutraceutical and cosmeceutical industries, announced today that it has closed a $2 Million private financing round with Canadian venture capital firm Avrio Ventures. This second round of financing from Avrio Ventures confirms the company’s growth potential. The funds will contribute to further advance the commercialization of Biopharmacopae’s flagship product RIDOVIR™ Cold and its other discoveries in the Canadian and International markets.

Biopharmacopae recently launched RIDOVIR™ Cold, a new cough and cold natural health product in several Canadian pharmacies. In addition, the company joined forces with well-known pharmacist and health expert Jean-Yves Dionne. The company is currently expanding its presence in the market by establishing additional commercial agreements with other pharmacies and large retail stores. “Biopharmacopae holds a portfolio of extremely promising products with significant market potential, and their recent studies on the antiviral activity of their cough and cold natural health product, RIDOVIR™ Cold, are very encouraging, says Mr. Aki Georgacacos, Partner at Avrio Ventures. In addition, with the company’s expertise and recent discovery, Biopharmacopae is well-positioned within the industry to become a strategic partner for companies looking for innovative products with great market potential.”

“We have created a technology platform adapted to the discovery of new health benefits related to plants and this gives us a competitive advantage when it comes to developing innovative health and beauty solutions” explains Dr. Johane Guay, Ph.D., Biopharmacopae’s President and CEO. Dr. Guay stated that she is extremely grateful for Avrio’s financial support and business and industry-related knowledge. “The solidity of our partnership with Avrio as well as their expertise and support are great assets to the existing strengths of the company. Together, we are currently pursuing further clinical research studies and intensifying our commercial efforts for RIDOVIR™ Cold in Canada and on the export markets.”

About Biopharmacopae
Biopharmacopae is a Canadian company known for the superior quality of its innovative plant-derived active ingredients and products. These products and ingredients are distributed through a worldwide network of partners recognized in the cosmetic and natural health product markets. The company develops and manufactures its products and active ingredients using a rigorous pharmaceutical approach that scientifically demonstrates their safety and efficacy. The company distinguishes itself with its original collection of over 15,000 plant extracts and with its exclusive technology platform, eXcelerate that allows for the rapid screening of thousands of plant extracts, highlighting their specific beneficial effects on human health. Biopharmacopae contributes to the advancement of science and improvement of the quality of life by developing natural products and ingredients that combine tradition and innovation.

About Avrio Ventures Management Corporation
Avrio Ventures provides Canada’s promising industrial bioproducts, nutraceutical ingredients and food technology companies with the investment support and resources they need to succeed. With a collective 80 years of experience in Canada’s industrial life science venture capital sector through the successes of FCC Ventures, a division of Farm Credit Canada, and Kirchner Investment Management Corporation, the Avrio team is well equipped with deep, sector-specific knowledge. Also providing strategic guidance, operational skills and access to industry relationship’s the Avrio team is uniquely qualified to support an entrepreneurial industrial life sciences organization throughout its growth.

About Mr Jean-Yves Dionne
Jean-Yves Dionne is a pharmacist, a scientific advisor and consultant in the natural health product (NHP) industry for several companies and professional groups. His research focuses on the interaction between NHPs and drugs as well as on conventional medicine and complementary or alternative medicine. He is the author or co-author of several books, including “Herbs, Everyday Reference for Health Professionals”.

14 February 2011 – AgraQuest and partners to introduce unique biofungicide for control of Black Sigatoka in Bananas

Calgary, Alberta 9 February 2011 – Botaneco Specialty Ingredients Inc. (“Botaneco”) is pleased to announce a formal partnership with Knowlton Development Corporation (“KDC”), a leading contract manufacturer serving North America’s most recognized personal care brands. Resulting from investment by KDC and Botaneco, Botaneco is launching Hydresia® O — a USDA National Organic Program (NOP) certified emulsifier based on Botaneco’s proprietary Oleosome technology. As a Quality Assurance International (QAI) certified processor and handler of USDA Organic personal care products, KDC will be the exclusive manufacturer of Hydresia® O formulations in this category as pertaining to their strategic customer base of national brand owners.

“KDC is a natural partner for Botaneco in this venture – having continuously invested in the R&D and manufacturing capabilities to develop and manufacture leading USDA-certified personal care products since 2009, they have the ability to take this category to the mass market. With this agreement Botaneco and KDC offer a joint turnkey solution that we anticipate will have a meaningful and innovative impact on the USDA NOP personal care market” stated Botaneco President and CEO Mike Stangel.

Oleosomes are isolated via physical processes, and are not chemically modified. As a result, they fall into a rare class of USDA organic eligible emulsifiers. Under the USDA NOP standards, chemical changes to a naturally occurring substance result in that substance being categorized as synthetic and ineligible for inclusion in certified organic products.

“One of the key formulation challenges for personal care companies looking to manufacture USDA organic personal care products is finding emulsifiers that allow them to achieve aesthetics on par with their current product offerings” added Dr. Jack Guth, VP R&D, Botaneco. “As substantiated by KDC, Hydresia® O will address this market need.”

QAI has completed an evaluation of Botaneco’s operations and has certified its Calgary facility organic in accordance with USDA NOP regulations. Both KDC and Botaneco have been independently certified by QAI as USDA NOP processors and handlers.

“Organic certification was made possible by the strong quality system framework in place at the Calgary manufacturing facility. Botaneco will continue to execute on its defined control principles to deliver products that consistently meet customer expectations” said Mike Stangel.

About Botaneco Specialty Ingredients Inc.
Botaneco is the global developer and marketer of innovative Oleosome-based ingredients to the personal care and OTC topical markets. As a technologically driven provider of high performance, proprietary ingredients, Botaneco is committed to developing innovative materials that offer multifunctional, tangible and documented benefits to both formulators and consumers. Botaneco’s head office and manufacturing facility is located in Calgary, Canada and its satellite office in Bensalem, PA. More information is available and can be accessed at www.botaneco.ca.

About KDC (Knowlton Development Corporation)
KDC (Knowlton Development Corporation), is a privately-owned holding company, and a growing force in the personal care contract manufacturing industry. Combining a dedicated market intelligence and innovation group, with several highly-scalable production facilities, KDC provides clients with the industry’s utmost service offering with over 1M square feet — and growing — of production and warehouse facilities. KDC’s growing family of companies includes LEKinc., TriTech Laboratories Inc., and Body Blue 2006 Inc. each offering optimal quality, value-engineered technologies and ultimate speed-to-market; key success factors for the industry’s top-500-listed companies.

For more on KDC (Knowlton Development Corporation) please visit their website at www.kdccompanies. com.

For further information contact:
Botaneco Specialty Ingredients Inc.
Mike Stangel
President and CEO
215-604-0631
stangelm@botaneco.ca

Knowlton Development Corporation
Ed Lobo
Sales & Business Development Manager
416-640-1957 x248
elobo@kdc-companies.com

19 January 2011 – Chromatin’s Yield Machine: is instant gene-stacking a game-changer for energy crops?